Literature DB >> 7733022

Fluoxetine increases resting energy expenditure and basal body temperature in humans.

R Bross1, L J Hoffer.   

Abstract

Humans lose weight when administered fluoxetine, an inhibitor of serotonin reuptake by nerve terminals. To determine whether increased energy expenditure contributes to this weight loss we admitted 20 nondepressed obese women to a metabolic unit where they were randomly assigned to 3 wk of a 1.76-MJ/d formula diet and either 60 mg fluoxetine/d or a placebo. Resting energy expenditure of the control subjects fell below normal after 5.6 +/- 0.6 d of energy restriction, whereas that of the fluoxetine-treated subjects increased by 4.4 +/- 1.8% (P < 0.005) within 3 d of commencing treatment. This increased resting energy expenditure then reversed and fell below normal after 9.8 +/- 0.9 d of energy restriction. Basal body temperature of the control subjects decreased insignificantly during the period of energy restriction, but that of the fluoxetine-treated subjects increased by 0.28 +/- 0.10 degrees C (P < 0.05) within 3 d of commencing diet and drug treatment. Urinary norepinephrine excretion and the serum triiodothyronine concentration decreased equally in both groups. Despite identical energy intakes and equal nitrogen balance, the fluoxetine-treated subjects lost weight faster than the control subjects during the final week of energy restriction (P < 0.05). We propose that serotonin reuptake inhibition increases energy expenditure by increasing basal body temperature.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7733022     DOI: 10.1093/ajcn/61.4.1020

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  15 in total

1.  Antidepressant use during pregnancy.

Authors:  P Boksa
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

Review 2.  Targeting brain serotonin synthesis: insights into neurodevelopmental disorders with long-term outcomes related to negative emotionality, aggression and antisocial behaviour.

Authors:  Klaus-Peter Lesch; Naozumi Araragi; Jonas Waider; Daniel van den Hove; Lise Gutknecht
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-09-05       Impact factor: 6.237

3.  Fluoxetine induces lean phenotype in rat by increasing the brown/white adipose tissue ratio and UCP1 expression.

Authors:  A I da Silva; G R F Braz; A A Pedroza; L Nascimento; C M Freitas; D J S Ferreira; R Manhães de Castro; C J Lagranha
Journal:  J Bioenerg Biomembr       Date:  2015-07-01       Impact factor: 2.945

Review 4.  Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.

Authors:  S M Cheer; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Metabolic effects of fluoxetine in obese menopausal women.

Authors:  M Bondi; R Menozzi; M Bertolini; M G Venneri; G Del Rio
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

Review 6.  Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.

Authors:  H Pijl; A E Meinders
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

7.  Fluoxetine exposure in adolescent and adult female mice decreases cocaine and sucrose preference later in life.

Authors:  Francisco J Flores-Ramirez; Israel Garcia-Carachure; David O Sanchez; Celene Gonzalez; Samuel A Castillo; Miguel A Arenivar; Anapaula Themann; Omar Lira; Minerva Rodriguez; Joshua Preciado-Piña; Sergio D Iñiguez
Journal:  J Psychopharmacol       Date:  2018-10-18       Impact factor: 4.153

8.  Serotonin transporter gene promoter polymorphism is associated with body mass index and obesity in non-elderly stroke patients.

Authors:  M Y Lan; Y Y Chang; W H Chen; Y F Kao; H S Lin; J S Liu
Journal:  J Endocrinol Invest       Date:  2009-02       Impact factor: 4.256

Review 9.  Ion channels and cancer.

Authors:  Karl Kunzelmann
Journal:  J Membr Biol       Date:  2005-06       Impact factor: 2.426

10.  Impacts of brain serotonin deficiency following Tph2 inactivation on development and raphe neuron serotonergic specification.

Authors:  Lise Gutknecht; Naozumi Araragi; Sören Merker; Jonas Waider; Frank M J Sommerlandt; Boris Mlinar; Gilda Baccini; Ute Mayer; Florian Proft; Michel Hamon; Angelika G Schmitt; Renato Corradetti; Laurence Lanfumey; Klaus-Peter Lesch
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.